Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Apr 11;133(15):1691-1694.
doi: 10.1182/blood-2018-10-878363. Epub 2019 Feb 4.

Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition

Olive S Eckstein  1   2 , Johannes Visser  3 , Carlos Rodriguez-Galindo  4   5 , Carl E Allen  1   2 ; NACHO-LIBRE Study Group
Collaborators, Affiliations
Comment

Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition

Olive S Eckstein et al. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: N.H. has served as a consultant for Novartis. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Outcomes of pediatric LCH patients treated with MAPK pathway inhibitors. (A) [18F]fluorodeoxyglucose–positron emission tomography scan from patient 17 with disseminated high-risk LCH before (left) and 2 months after (right) treatment with vemurafenib, scored as a partial metabolic response. (B) Magnetic resonance imaging brain (axial T2 fluid-attenuated inversion recovery) from patient 6 with radiologic LCH-ND before (right) and 7 months after (left) treatment with vemurafenib, scored as a partial radiologic response. (C) Graphic representation of progression-free survival (PFS) time (37%) for all patients treated with MAPK inhibition (MAPKi; n = 21). (D) Individual swimmer plots for each patient (n = 21), depicting PFS with MAPKi. Responses for patients (5 and 13) who had both LCH-ND and systemic LCH at start of MAPKi are subdivided as follows: 5.1, swimmer plot for LCH-ND; 5.2, swimmer plot for parietal bone lesion; 13.1, swimmer plot for LCH-ND; 13.2, swimmer plot for LCH liver involvement. BMT, bone marrow transplantation.
See this image and copyright information in PMC

Comment on

  • Recurrent BRAF mutations in Langerhans cell histiocytosis.
    Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ. Badalian-Very G, et al. Blood. 2010 Sep 16;116(11):1919-23. doi: 10.1182/blood-2010-04-279083. Epub 2010 Jun 2. Blood. 2010. PMID: 20519626 Free PMC article.

References

    1. Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. N Engl J Med. 2018;379(9):856-868. - PMC - PubMed
    1. Gadner H, Minkov M, Grois N, et al. ; Histiocyte Society. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121(25):5006-5014. - PubMed
    1. Haupt R, Nanduri V, Calevo MG, et al. . Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer. 2004;42(5):438-444. - PubMed
    1. Yeh EA, Greenberg J, Abla O, et al. . Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. Pediatr Blood Cancer. 2018;65(1):26784. - PubMed
    1. Badalian-Very G, Vergilio JA, Degar BA, et al. . Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919-1923. - PMC - PubMed

Substances